A database built with INDRA combining content from numerous readers and databases. This page allows you to curate the loaded statements. For more information please see the manual.



phosphosite cbn pc11 biopax bel_lc signor biogrid tas lincs_drug hprd trrust | geneways tees isi trips rlimsp medscan sparser reach

BRAF binds EGFR, KRAS, and NRAS. 2 / 2
| 2
"In addition, secondary resistance develops in all patients and is associated with the development of secondary KRAS , NRAS , EGFR or BRAF mutations ( xref , xref , xref )."
"We then exploited the GDSC database and found that in a variety of cancer cells, mutations in KRAS, NRAS, and BRAF were associated with resistance to common EGFR inhibitors like Gefitinib and Afatinib, in spite of some mutations that did not pass false discovery rate (FDR), possibly due to complexity of genetic background throughout so many cancer types ( xref ; xref )."